Emily Bethea

Emily Bethea

Auto-generated profile, based on publicly available information

Emily Bethea

Liver Center, Gastroenterology Division, Massachusetts General Hospital, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
EBEmily Bethea
Emily Bethea
AAAshwini Arvind
Ashwini Arvind
JGJenna Gustafson
Jenna Gustafson
KAKarin Andersson
Karin Andersson
DPDaniel Pratt
Daniel Pratt
RCRaymond T. Chung
Raymond T. Chung
The practice of transplanting hepatitis C (HCV)-infected livers into HCV-uninfected recipients has not previously been recommended in transplant guidelines, in part because of concerns over uncontrolled HCV infection of the allograft. Direct-acting antivirals (DAAs) provide an opportunity to treat donor-derived HCV-infection and should be administered early in the posttransplant period. However, evidence on the safety and efficacy of an immediate DAA treatment approach, including how to manage logistical barriers surrounding timely DAA procurement, are required prior to broader use of HCV-positive donor organs. We report the results of a trial in which 14 HCV-negative patients underwent successful liver transplantation from HCV-positive donors. Nine patients received viremic (nucleic acid testing [NAT]-positive) livers and started a 12-week course of oral glecaprevir-pibrentasvir within 5 days of transplant. Five patients received livers from HCV antibody-positive nonviremic donors and were followed using a reactive approach. Survival in NAT-positive recipients is 100% at a median follow-up of 46 weeks. An immediate treatment approach for HCV NAT-positive liver transplantation into uninfected recipients is safe and efficacious. Securing payer approval for DAAs early in the posttransplant course could enable need-based allocation of HCV-positive donor organs irrespective of candidate HCV status, while averting chronic HCV allograft infection.

1 January 2024 in Hepatology Communications
Verified
Journal Article
Open access
NUNneka N. Ufere
Nneka N. Ufere
CLCarlos Lago-Hernandez
Carlos Lago-Hernandez
AAAlysa Alejandro-Soto
Alysa Alejandro-Soto
TWTiana Walker
Tiana Walker
LLLucinda Li
Lucinda Li
MSMarina Serper
Marina Serper
Background: Health care–related transportation insecurity (delayed or forgone medical care due to transportation barriers) is being increasingly recognized as a social risk factor affecting health outcomes. We estimated the national burden and adverse outcomes of health care–related transportation insecurity among US adults with chronic liver disease (CLD). Methods: Using the U.S. National Health Interview Survey from 2014 to 2018, we identified adults with self-reported CLD. We used complex weighted survey analysis to obtain national estimates of health care–related transportation insecurity. We examined the associations between health care–related transportation insecurity and health care–related financial insecurity, food insecurity, self-reported health status, work productivity, health care use, and mortality. Results: Of the 3643 (representing 5.2 million) US adults with CLD, 267 [representing 307,628 (6%; 95% CI: 5%–7%)] reported health care–related transportation insecurity. Adults with CLD experiencing health care–related transportation insecurity had 3.5 times higher odds of cost-related medication nonadherence [aOR, 3.5; (2.4–5.0)], 3.5 times higher odds of food insecurity [aOR, 3.5; (2.4–5.3)], 2.5 times higher odds of worsening self-reported health status over the past year [aOR, 2.5; (1.7–3.7)], 3.1 times higher odds of being unable to work due to poor health over the past year [aOR, 3.1; (2.0–4.9)], and 1.7 times higher odds of being in a higher-risk category group for number of hospitalizations annually [aOR, 1.7; (1.2–2.5)]. Health care–related transportation insecurity was independently associated with mortality after controlling for age, income, insurance status, comorbidity burden, financial insecurity, and food insecurity [aHR, 1.7; (1.4–2.0)]. Conclusions: Health care–related transportation insecurity is a critical social risk factor that is associated with health care–related financial insecurity, food insecurity, poorer self-reported health status and work productivity, and increased health care use and mortality among US adults with CLD. Efforts to screen for and reduce health care–related transportation insecurity are warranted. Export

2 November 2021 in Transplant International
Verified
Journal Article
Closed access
PDF file
QYQing Yuan
Qing Yuan
HCHanwen Cui
Hanwen Cui
GLGreg A. Leya
Greg A. Leya
SHShanjuan Hong
Shanjuan Hong
EREve M. Roth
Eve M. Roth
NENahel Elias
Nahel Elias
Background Direct-acting antivirals (DAA) transformed hepatitis C virus (HCV) treatment in 2014, however their impact on transplant candidates' willingness-to-accept (CWTA) organs from HCV+ donors remain uncertain. Study Design We retrospectively studied Organ Procurement and Transplantation Network data from 2008-2019, investigating CWTA different organs from HCV+ donors over time, using segmented multivariable logistic regression, and how that influenced wait-time and deceased donor transplantation (DDTx) probability, using multivariable logistic or linear regression. Results We found that DAA availability was associated with a marked increase in CWTA all organs from HCV+ donors except intestine. By December 2020, 40% of kidney, 33% of kidney-pancreas, 42% of pancreas, over 50% of liver, heart, lung, heart-lung, and 9% of intestine candidates waitlisted were CWTA an organ from HCV+ donors. Compared to pre-DAA, yearly CWTA kidney from HCV+ donors increased post-DAA 1.781.811.83-fold, kidney-pancreas 2.52 2.78 3.07-fold, pancreas 3.153.69 4.43-fold, liver 1.531.541.56-fold, heart 1.92 2.02.08 -fold, and lung 2.002.12.20 -fold. CWTA kidney and liver from HCV+ donors significantly increased DDTx probability post-DAA (1.982.042.1-fold, 1.241.291.33-fold, respectively) and shortened kidney candidates wait-time7890101 days (Mean with 95%CI). Conclusion CWTA organs from HCV+ donors rose significantly with DAA availability, benefitting kidney and liver candidates with increased DDTx rates and shortened kidney candidates wait time. Further long-term outcomes investigation and standardized organ from HCV+ donors’ education could improve both provider and patient acceptance and utilization.

17 May 2022 in medRxiv
Verified
Preprint
Open access
PDF file
AJAyman Al Jurdi
Ayman Al Jurdi
LMLeela Morena
Leela Morena
MCMariesa Cote
Mariesa Cote
EBEmily Bethea
Emily Bethea
JAJamil Azzi
Jamil Azzi
LRLeonardo V. Riella
Leonardo V. Riella
The neutralizing monoclonal antibody combination of tixagevimab/cilgavimab has been shown to reduce the risk of SARS-CoV-2 infection in unvaccinated individuals during the Alpha (B.1.1.7) and Delta (B.1.617.2) waves. However, data on efficacy and safety of tixagevimab/cilgavimab in vaccinated solid organ transplant recipients during the Omicron wave is limited. To address this, we conducted a retrospective cohort study comparing 222 solid organ transplant recipients who received tixagevimab/cilgavimab for pre-exposure prophylaxis and 222 age-matched vaccinated solid organ transplant recipients who did not receive tixagevimab/cilgavimab. Subjects were followed for a mean of 67 ± 18 days. Kaplan-Meier estimates of the 60-day incidence of breakthrough infection were 1.8% in the tixagevimab/cilgavimab group and 4.7% in the control group ( P = 0.045). Adverse events were uncommon, occurring in 4% of our cohort and most were mild. There was no significant change in serum creatinine or liver chemistries in kidney and liver transplant recipients respectively. In conclusion, we found that tixagevimab/cilgavimab use is safe and associated with a lower risk of breakthrough SARS-CoV-2 infection in vaccinated solid organ transplant recipients during the Omicron wave.

23 May 2023 in Hepatology Communications
Verified
Journal Article
Open access
PBPatricia Bloom
Patricia Bloom
TGTimothy Gilbert
Timothy Gilbert
KSKeli Santos-Parker
Keli Santos-Parker
ZMZoe Memel
Zoe Memel
EPEric Przybyszewski
Eric Przybyszewski
SWSeth Waits
Seth Waits
Background: Ascites is common in cirrhosis but uncommon after liver transplant. We aimed to characterize the incidence, natural history, and current management strategies of post-transplant ascites. Methods: We performed a retrospective cohort study of patients who underwent liver transplantation at 2 centers. We included patients who underwent deceased donor whole graft liver transplants between 2002 and 2019. Chart review identified patients with post-transplant ascites, requiring a paracentesis between 1 and 6-month post-transplants. Detailed chart review identified clinical and transplant characteristics, evaluation of ascites etiology, and treatments. Results: Of 1591 patients who successfully underwent a first-time orthotopic liver transplant for chronic liver disease, 101 (6.3%) developed post-transplant ascites. Only 62% of these patients required large volume paracentesis for ascites before transplant. 36% of patients with post-transplant ascites had early allograft dysfunction. Most patients with post-transplant ascites (73%) required a paracentesis within 2 months of transplant, but 27% had delayed ascites onset. From 2002 to 2019, ascites studies were obtained less often, and hepatic vein pressure measurement was performed more often. Diuretics were the mainstay of treatment (58%). The use of albumin infusion and splenic artery embolization to treat post-transplant ascites increased over time. Larger pre-transplant spleen size was associated with a greater number of post-transplant paracenteses (r=0.32 and p=0.003). For patients who underwent splenic intervention, paracentesis frequency was significantly reduced (1.6–0.4 paracenteses/month, p=0.0001). The majority (72%) of patients had clinical resolution of their ascites at 6-month post-transplant. Conclusions: Persistent or recurrent ascites continues to be a clinical issue in the modern era of liver transplantation. Most had clinical resolution within 6 months, some requiring intervention.

10 March 2025 in Transplantation Direct
Verified
Journal Article
Open access
MCMaria P. Cote
Maria P. Cote
DCDaniel Cloonan
Daniel Cloonan
SLSienna Bs Li
Sienna Bs Li
SRShahaan Bs Razak
Shahaan Bs Razak
RSRuby Singh
Ruby Singh
LDLeigh Anne Dageforde
Leigh Anne Dageforde
Background.: Liver transplantation (LT) is the standard treatment for liver failure secondary to alcohol-associated liver disease, but limited literature and best practices exist for post-LT treatment of alcohol use disorder (AUD). This study explores current AUD management practices and providers’ perceived barriers to effective post-LT AUD management. Methods.: A 45-item survey on post-LT AUD treatment practices was distributed to members of the American Society of Transplant Surgeons, the Association of Consult/Liaison Psychiatry Transplant Special Interest Group, and both the American Society of Transplantation’s Liver and Intestine Community of Practice and Psychosocial and Ethics Community of Practice discussion boards, between December 2021 and April 2022. Univariate analysis of categorical variables was performed using the chi-square test. Data were analyzed using center volume tertiles, country region, and provider professional activity. Results.: Two hundred thirty-two respondents from 70 LT centers across all 11 United Network for Organ Sharing regions completed the survey. Half of the them were attending physicians and 16.4% were nurse coordinators. Most centers (84%) aimed for alcohol abstinence for all post-LT patients. Perceived barriers to AUD treatment efficacy included ongoing desire to drink (18%), denial about alcohol misuse (14.9%), and lack of posttransplant support (14%). Additionally, 62.1% of centers had no policy for prescribing medication-assisted therapy to treat AUD, and 32.7% of centers reported no center-level changes in AUD care. Providers identified primary needs as hiring additional mental health professionals (30.8%), dedicating specific staff to AUD care (24.7%), and standardizing psychiatric/psychological care in transplant clinics (17.2%). Conclusions.: Despite the increasing volume of LT for alcohol-associated liver disease, significant perceived barriers to effective AUD treatment remain.